Thelansis

EGFR-Non-Small Cell Lung Cancer Market Outlook Thelansis’s “EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential EGFR-Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

 Patients with Non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation constitute a distinct cohort. Their cancer's etiology, clinicopathological characteristics, prognosis, and treatment approaches diverge from other NSCLC patients. EGFR mutations manifest in approximately 40%–60% of Southeast Asian individuals or 10%–20% of Caucasians diagnosed with lung adenocarcinomas. While prevalent among non-smokers or light smokers, EGFR mutation-positive tumors may also occur in other smoking profiles. Notably, the rise in non-smoking habits has led to a higher proportion of female patients exhibiting EGFR mutations compared to males. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non-smokers or non-smokers with lung adenocarcinoma, females constituted 80% of the participant pool.   Thelansis’s “EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 ...